



## Clinical trial results:

**A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerability, efficacy and pharmacokinetics of GLPG3970, administered orally for 6 weeks in adult subjects with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate**

### Summary

EudraCT number	2020-000658-83
Trial protocol	BG
Global end of trial date	07 April 2021

### Results information

Result version number	v1 (current)
This version publication date	06 April 2022
First version publication date	06 April 2022

### Trial information

#### Trial identification

Sponsor protocol code	GLPG3970-CL-209
-----------------------	-----------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04577781
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Galapagos NV
Sponsor organisation address	Generaal De Wittelaan L11 A3, Mechelen, Belgium, 2800
Public contact	Galapagos Medical Information, Galapagos NV, medicalinfo@glpg.com
Scientific contact	Galapagos Medical Information, Galapagos NV, medicalinfo@glpg.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	07 April 2021
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	07 April 2021
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To evaluate the effect of GLPG3970 compared to placebo on the signs and symptoms of Rheumatoid Arthritis (RA) in participants with moderately to severely active RA and an inadequate response to methotrexate (MTX).

Protection of trial subjects:

Clinical study was conducted in accordance with the ethical principles that have their origin in the "Declaration of Helsinki" and its amendments in force at the time of the clinical study (2013 version). It was also carried out in conformity with the protocol, the International Council for Harmonization for Good Clinical Practice (ICH-GCP) Guideline E6 (R2), and local ethical and legal requirements. The investigator informed the subjects of the risks and benefits of the clinical study. The subjects were informed that they could withdraw from the clinical study at any time for any reason. Consent was obtained in writing prior to any clinical study-related activities; the investigator retained a copy of the ICFs, which are available to the sponsor for review. The subjects were covered by the sponsor's insurance according to local legal requirements.

Background therapy:

Participants remained on a stable dose (10 to 20 mg/week) of MTX as background medication.

Evidence for comparator: -

Actual start date of recruitment	12 October 2020
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 1
Country: Number of subjects enrolled	Bulgaria: 4
Country: Number of subjects enrolled	Georgia: 6
Country: Number of subjects enrolled	Ukraine: 17
Worldwide total number of subjects	28
EEA total number of subjects	5

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	28
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Study was conducted across 4 countries (Georgia, Poland, Bulgaria, and Ukraine).

### Pre-assignment

Screening details:

A total of 54 participants were screened, out of which 28 were randomized and treated.

### Period 1

Period 1 title	Overall study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Carer

### Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	GLPG3970
------------------	----------

Arm description:

Participants received 400 milligrams (mg) GLPG3970 oral solution, once daily (QD) for a period of 6 weeks.

Arm type	Experimental
Investigational medicinal product name	GLPG3970
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for oral solution
Routes of administration	Oral use

Dosage and administration details:

Participants received 400 mg GLPG3970 reconstituted oral solution, QD for a period of 6 weeks.

<b>Arm title</b>	Placebo
------------------	---------

Arm description:

Participants received GLPG3970 matching placebo oral solution, QD for a period of 6 weeks.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for oral solution
Routes of administration	Oral use

Dosage and administration details:

Participants received GLPG3970 matching placebo reconstituted oral solution, QD for a period of 6 weeks.

<b>Number of subjects in period 1</b>	GLPG3970	Placebo
Started	16	12
Completed	13	10
Not completed	3	2
Physician decision	1	-
Adverse event, non-fatal	2	2

## Baseline characteristics

### Reporting groups

Reporting group title	GLPG3970
Reporting group description:	
Participants received 400 milligrams (mg) GLPG3970 oral solution, once daily (QD) for a period of 6 weeks.	
Reporting group title	Placebo
Reporting group description:	
Participants received GLPG3970 matching placebo oral solution, QD for a period of 6 weeks.	

Reporting group values	GLPG3970	Placebo	Total
Number of subjects	16	12	28
Age categorical Units: Subjects			
Age continuous Units: years arithmetic mean standard deviation	45.9 ± 11.3	41.4 ± 8.6	-
Gender categorical Units: Subjects			
Female	11	8	19
Male	5	4	9
Race Units: Subjects			
White	16	12	28
Ethnicity Units: Subjects			
Not Hispanic or Latino	16	12	28
Disease Activity Score Based on 28 Joints C-reactive Protein [DAS28 (CRP)]			
<p>The DAS28 (CRP) is a derived measurement with differential weighting given to each component such as Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), patient's global assessment of disease activity, and serum CRP level.</p> <p><math>DAS28 (CRP) = 0.56 \times \text{square root of TJC28} + 0.28 \times \text{square root of SJC28} + 0.36 \times \ln[1 + CRP(\text{in mg/L})] + 0.014 \times \text{patient's disease activity VAS (in mm)} + 0.96</math>. A lower score is considered as better disease activity.</p>			
Units: Score on a scale arithmetic mean standard deviation	6.13 ± 0.87	5.68 ± 0.88	-

## End points

### End points reporting groups

Reporting group title	GLPG3970
Reporting group description: Participants received 400 milligrams (mg) GLPG3970 oral solution, once daily (QD) for a period of 6 weeks.	
Reporting group title	Placebo
Reporting group description: Participants received GLPG3970 matching placebo oral solution, QD for a period of 6 weeks.	

### Primary: Change From Baseline in DAS28 (CRP) at Week 6

End point title	Change From Baseline in DAS28 (CRP) at Week 6
End point description: The DAS28 (CRP) is a derived measurement with differential weighting given to each component such as TJC28, SJC28, patient's global assessment of disease activity, and serum CRP level. TJC28 ranges from 0-28 SJC28 ranges from 0-28 High sensitivity C-reactive protein (hsCRP) (in mg/L) Patient's disease activity VAS (in mm) (ranges from 0 = best to 100 = worst) The DAS28 (CRP) score was calculated using the below formula: $\text{DAS28 (CRP)} = 0.56 \times \text{square root of TJC28} + 0.28 \times \text{square root of SJC28} + 0.36 \times \text{Ln}[1 + \text{CRP (in mg/L)}] + 0.014 \times \text{patient's disease activity VAS (in mm)} + 0.96.$ A lower score is considered as better disease activity.  Analysis population: Full analysis set (FAS) consisted of all randomized participants who had been administered at least 1 dose of investigational product. Participants with available data at specified timepoint were included.	
End point type	Primary
End point timeframe: Baseline and Week 6	

End point values	GLPG3970	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	13	10		
Units: Score on a scale				
least squares mean (standard error)	-1.29 ( $\pm$ 0.224)	-1.24 ( $\pm$ 0.258)		

### Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	GLPG3970 v Placebo

Number of subjects included in analysis	23
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.885 <sup>[1]</sup>
Method	MMRM
Parameter estimate	Least Squares (LS) Mean difference
Point estimate	-0.05
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.66
upper limit	0.55
Variability estimate	Standard error of the mean
Dispersion value	0.353

Notes:

[1] - Mixed model repeated measure (MMRM) with treatment-by-visit interaction and baseline-by-visit interaction as fixed effects (with an unstructured variance-covariance matrix).

## Secondary: Number of Participants With Treatment Emergent Adverse Events

End point title	Number of Participants With Treatment Emergent Adverse Events
-----------------	---

End point description:

Treatment-Emergent Adverse Events (TEAE) were defined as

- Any adverse event (AE) with an onset date on or after the IP start date and no later than 14 days after last dose of IP, or worsening of any AE on or after the IP start date.
- Improvement or no change of any ongoing AEs on or after the IP start date are not considered treatment-emergent. If an AE was ongoing at the time of first IP intake and if there was no change or an improvement in its toxicity grade or its seriousness status, this AE was not considered as treatment-emergent.

Serious TEAE was defined as a TEAE that

- Resulted in death and was life-threatening;
- Required in-patient hospitalization or prolongation of existing hospitalization;
- Resulted in persistent or significant disability/incapacity;
- Was a congenital anomaly / birth defect;
- Was medically significant;

Analysis population: Participants in the safety analysis set.

End point type	Secondary
----------------	-----------

End point timeframe:

From first dose of study drug until end of the study (up to 8 weeks)

End point values	GLPG3970	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	16	12		
Units: Participants				
TEAE	6	2		
Serious TEAE	0	0		
TEAE leading to death	0	0		
Treatment related TEAE	4	1		
TEAEs leading to study drug discontinuation	2	0		



## Statistical analyses

No statistical analyses for this end point

## Secondary: Plasma Concentration (Ctough) of GLPG3970

End point title	Plasma Concentration (Ctough) of GLPG3970 <sup>[2]</sup>
-----------------	--

End point description:

Ctough was defined as plasma concentration level at the end of the dosing interval.

Analysis Population: Pharmacokinetic analysis set (PKAS) consisted all participants who received at least 1 dose of investigational product with available plasma concentration data. Participants with available plasma concentration at specified time point were included.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 15: pre-dose; Day 29: pre-dose; Day 43: pre-dose

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint assessed plasma concentration (Ctough) of GLPG3970. Therefore, it is applicable for GLPG3970 arm only.

End point values	GLPG3970			
Subject group type	Reporting group			
Number of subjects analysed	11 <sup>[3]</sup>			
Units: Nanogram per milliliter				
geometric mean (geometric coefficient of variation)				
Day 15: Pre-dose	95.3 (± 115)			
Day 29: Pre-dose	103 (± 73.8)			
Day 43: Pre-dose	49.8 (± 697)			

Notes:

[3] - n = 11 at day 15, 9 at day 29, 9 at day 43

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From first dose of study drug until end of the study (up to 8 weeks)

Adverse event reporting additional description:

Safety analysis set

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23.1
--------------------	------

### Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Participants received GLPG3970 matching placebo oral solution, QD for a period of 6 weeks.

Reporting group title	GLPG3970
-----------------------	----------

Reporting group description:

Participants received 400 mg GLPG3970 oral solution, QD for a period of 6 weeks.

Serious adverse events	Placebo	GLPG3970	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 12 (0.00%)	0 / 16 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Placebo	GLPG3970	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	2 / 12 (16.67%)	6 / 16 (37.50%)	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 12 (0.00%)	2 / 16 (12.50%)	
occurrences (all)	0	2	
Lipase increased			
subjects affected / exposed	1 / 12 (8.33%)	1 / 16 (6.25%)	
occurrences (all)	1	1	
SARS-CoV-2 test positive			

subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 16 (6.25%) 1	
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	1 / 12 (8.33%)	0 / 16 (0.00%)	
occurrences (all)	1	0	
Dyspepsia			
subjects affected / exposed	0 / 12 (0.00%)	2 / 16 (12.50%)	
occurrences (all)	0	2	
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 12 (0.00%)	1 / 16 (6.25%)	
occurrences (all)	0	1	
Hepatitis			
subjects affected / exposed	0 / 12 (0.00%)	1 / 16 (6.25%)	
occurrences (all)	0	1	
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	1 / 12 (8.33%)	0 / 16 (0.00%)	
occurrences (all)	1	0	
COVID-19			
subjects affected / exposed	1 / 12 (8.33%)	0 / 16 (0.00%)	
occurrences (all)	1	0	
Pharyngitis			
subjects affected / exposed	0 / 12 (0.00%)	1 / 16 (6.25%)	
occurrences (all)	0	1	
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	0 / 12 (0.00%)	1 / 16 (6.25%)	
occurrences (all)	0	1	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported